Marijuana Use Trends: In Pregnancy and Among Adult General Population

By |2021-11-11T17:15:47-08:00December 20th, 2016|Brief Bulletins from the Field, We Know Psychiatry|

Trends in Marijuana Use Among Pregnant and Nonpregnant Reproductive-Aged Women, 2002-2014 Qiana L. Brown, Aaron L. Sarvet, Dvora Shmulewitz Methods The Columbia University Medical Center institutional review board waived review of this study. Informed oral consent was obtained from each participant. Data from women aged 18 through 44 years from the annual National Survey on [...]

Personality Traits Tied to Genome Areas & Mental Illness

By |2021-11-11T17:15:56-08:00December 20th, 2016|Brief Bulletins from the Field, We Know Psychiatry|

Researchers have identified six regions of the human genome that are significantly linked to personality traits, and some show significant correlations to certain psychiatric disorders as well. The study, conducted by researchers at the University of California San Diego School of Medicine, is based on a meta-analysis of genome-wide association [...]

Shortcuts to Addiction

By |2021-11-11T17:16:05-08:00December 8th, 2016|Brief Bulletins from the Field, We Know Psychiatry|

Psychiatrist Anna Lembke, chief of addiction medicine at Stanford University’s medical school, has spent her career helping patients battle their addiction to opioid drugs, from Vicodin to heroin. Out of this experience comes “Drug Dealer, MD,” a short and feisty book in which, among much else, she calls out practitioners [...]

Vagus Nerve Stimulation: Handheld Device in the Works to Heal the Body

By |2021-11-11T17:16:12-08:00December 6th, 2016|Brief Bulletins from the Field, We Know Psychiatry|

Every breath we take, especially the slow, deep breathing used in meditation, stimulates the vagus nerve to calm the body. Scientists also believe stimulating the nerve with small electrical impulses can have far reaching potential to treat medical conditions including migraines, rheumatoid arthritis and strokes. Targeting nerves for treatment is [...]

Ecstasy (MDMA) and Hallucinogenic (Psilocybin) Show Significant Psychiatric Benefits for PTSD and Cancer Patients

By |2021-11-11T17:16:19-08:00December 2nd, 2016|Brief Bulletins from the Field, We Know Psychiatry|

Promising research into PTSD and the psychological effects of cancer such as anxiety and depression, have cast new light on the party drug, ecstasy (MDMA), and a hallucinogenic ingredient in "Magic Mushrooms" (psilocybin). In a paper posted online, Michael and Ann Mithoefer, the husband-and-wife team offering the treatment — which combines [...]

Surgeon General’s Report: Toll on Addictions top $400 Billion, Few are Treated

By |2021-11-11T17:16:28-08:00November 18th, 2016|Brief Bulletins from the Field, We Know Psychiatry|

While the debate rages whether the drug epidemic in the United States is best served by walls or treatment, millions of Americans suffer from alcoholism or addiction to legal and illegal drugs, but only a fraction are being treated, according to a report released on Thursday by the surgeon general. [...]

Do Like Yogis: Controlled Breathing is a ‘Scientific’ Source of Relief

By |2021-11-11T17:16:36-08:00November 15th, 2016|Brief Bulletins from the Field, We Know Psychiatry|

For centuries yogis have used breath control, or pranayama, to promote concentration and improve vitality. Buddha advocated breath-meditation as a way to reach enlightenment. Science is just beginning to provide evidence that the benefits of this ancient practice are real. Studies have found, for example, that breathing practices can help [...]

ABSTRACTS, VOLUME 42, NUMBER 1

By |2009-01-12T19:31:54-08:00January 12th, 2009|Brief Bulletins from the Field, We Know Psychiatry|

Psychopharmacology BULLETIN Newsletter the advance newsletter of Psychopharmacology BULLETIN Summary—Index of This Issue On-Press ORIGINAL RESEARCH EVIDENCE-BASED MEDICINEORIGINAL RESEARCH: The Trials and Travails Atypical Antipsychotic Drugs and Diabetes in the US Adverse Event Database Bipolar-I Patient Characteristics PTSD Following Short-Term Paroxetine Treatment Aripiprazole in the Treatment of PTSD Memantine: An [...]

Psychopharmacology Bulletin Newsletter 4

By |2008-11-24T19:26:09-08:00November 24th, 2008|Brief Bulletins from the Field, We Know Psychiatry|

• ORIGINAL RESEARCH • EVIDENCE BASED MEDICINE • GENERAL PSYCHIATRY Seroquel Once a Day: A Randomized, Double-Blind, Placebo-Controlled Study— This 6-week, randomized, double-blind study aimed to demonstrate efficacy of once-daily extended release quetiapine fumarate (quetiapine XR) versus placebo in patients with acute schizophrenia resulting in the efficacy of quetiapine XR [...]

Psychopharmacology Bulletin Newsletter 3

By |2008-10-20T19:42:08-07:00October 20th, 2008|Brief Bulletins from the Field, We Know Psychiatry|

  Newsletter No. 3, 2008 www.psychopharmbulletin.com Volume 41 • Number 3 • 2008 Psychopharmacology BULLETIN Newsletter the advance newsletter of Psychopharmacology BULLETIN Summary—Index of This Issue On-Press ORIGINAL RESEARCH EVIDENCE BASED MEDICINE Cocaine is a Major Risk Factor for Antipsychotic Induced Akathisia, Parkinsonism and Dyskinesia abstract ~ Objective: To assess [...]

Go to Top